The contracts administered at the
"Diplomat continues to support manufacturers with specialty drug and digital therapeutics services,"
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance, and may include Diplomat's expectations regarding the results of business or asset dispositions, impact of actions to reduce indebtedness, expected benefits and performance of business and growth strategies, the strategic alternatives review process and potential transactions that may be identified and explored as a result of such review process, impact of operational improvement initiatives and results of operational and capital expenditures. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. These risks and uncertainties include: our ability to adapt to changes or trends within the specialty pharmacy industry; our relationships with wholesalers and key pharmaceutical manufacturers; our debt service obligations; maintaining compliance with our amended credit facility covenants; increased financing and other costs; investments in new business strategies and initiatives, including with respect to data and analytics capabilities, could disrupt our ongoing business and present risks not originally contemplated; potential disruption to our workforce and operations due to cost savings and restructuring initiatives; the ability to identify and consummate strategic alternatives that yield additional value for shareholders; the timing, benefits and outcome of the Company's ongoing strategic alternatives review process, including the determination of whether or not to pursue or consummate any strategic alternative; the structure, terms and specific risks and uncertainties associated with any potential strategic transaction; potential disruptions in our business and the stock price as a result of our exploration, review and pursuit of strategic alternatives or the public announcement thereof and any decision or transaction resulting from such review, including potential disruptions with respect to our employees, vendors, clients and customers; and the additional factors set forth in "Risk Factors" in Diplomat's most recent Annual Report on Form 10-K and in subsequent reports filed with or furnished to the
About Diligent Health Solutions
Founded by Life Science industry veterans
312.889.5244 | [email protected]
810.768.9282 | [email protected]
View original content to download multimedia:http://www.prnewswire.com/news-releases/diplomat-announces-sale-of-certain-assets-of-envoy-health-management-llc-to-diligent-health-solutions-llc-300940014.html